

AMENDMENT AND RESPONSE TO OFFICE ACTION

Amendment

In the Claims

Claims 1-32. (Canceled)

33. (Currently amended) A method for delivering monomeric or dimeric insulin to a patient in need thereof, comprising administering to the patient a delivery formulation for the monomeric or dimeric insulin comprising an effective amount of insulin complexed with a diketopiperazine derivative, wherein the delivery formulation is prepared by complexing the insulin with microparticles of the diketopiperazine derivative, wherein the diketopiperazine derivative has the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, and glutaryl, and

wherein the microparticles release monomeric or dimeric insulin upon dissociation.

Claim 34. (Canceled)

35. (Previously presented) The method of claim 33 wherein X is fumaryl.

36. (Previously presented) The method of claim 33 wherein X is succinyl.

37. (Previously presented) The method of claim 33 wherein X is maleyl.

38. (Previously presented) The method of claim 33 wherein X is glutaryl.

39. (Previously presented) The method of claim 33 wherein the composition is in a dry powder form administered to the lungs via inhalation.

40. (Previously presented) The method of claim 33 wherein the patient is a Type II diabetic.

AMENDMENT AND RESPONSE TO OFFICE ACTION

41. (Previously presented) The method of claim 40 wherein the composition is administered concurrently with, or less than about 20 minutes prior to, the patient eating a meal.

42. (Previously presented) The method of claim 33 wherein the composition is provided in one or more unit doses of insulin, each dose equivalent to about 6 IU of insulin.